Selected research
Market Outlook & Growth Opportunities
Global CAR T-Cell Therapy Market Outlook and Growth Opportunities 2026
Market perspective
The global CAR T-Cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for CAR T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for CAR T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for CAR T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the CAR T-Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the CAR T-Cell Therapy market include J & J, Novartis, Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), JW Therapeutics, Gilead Sciences, FOSUNKite, Celyad(Pipeline) and Cellectis(Pipeline), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global CAR T-Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of CAR T-Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents CAR T-Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CAR T-Cell Therapy market.
CAR T-Cell Therapy Segment by Company
J & J
Novartis
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
JW Therapeutics
Gilead Sciences
FOSUNKite
Celyad(Pipeline)
Cellectis(Pipeline)
CARsgen Therapeutics (Pipeline)
Bristol-Myers Squibb
Bluebird Bio(Pipeline)
Autolus Therapeutics(Pipeline)
Allogene Therapeutics(Pipeline)
CAR T-Cell Therapy Segment by Type
CD19 - Targeted
BCMA - Targeted
CAR T-Cell Therapy Segment by Application
Lymphoma
Multiple Myeloma
CAR T-Cell Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global CAR T-Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the CAR T-Cell Therapy key companies, revenue, market share, and recent developments.
3. To split the CAR T-Cell Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions CAR T-Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify CAR T-Cell Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze CAR T-Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CAR T-Cell Therapy industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of CAR T-Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of CAR T-Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. CAR T-Cell Therapy Industry Trends
Table 2. CAR T-Cell Therapy Industry Drivers
Table 3. CAR T-Cell Therapy Industry Opportunities and Challenges
Table 4. CAR T-Cell Therapy Industry Restraints
Table 5. Global CAR T-Cell Therapy Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global CAR T-Cell Therapy Revenue Share by Company (2021-2026)
Table 7. Global CAR T-Cell Therapy Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global CAR T-Cell Therapy Key Company Manufacturing Base & Headquarters
Table 9. Global CAR T-Cell Therapy Company, Product Type & Application
Table 10. Global CAR T-Cell Therapy Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global CAR T-Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of CD19 - Targeted
Table 15. Significant Companies of BCMA - Targeted
Table 16. Global CAR T-Cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 17. Global CAR T-Cell Therapy Sales Value by Type (2021-2026) & (US$ Million)
Table 18. Global CAR T-Cell Therapy Sales Value by Type (2027-2032) & (US$ Million)
Table 19. Global CAR T-Cell Therapy Sales Value Share by Type (2021-2026)
Table 20. Global CAR T-Cell Therapy Sales Value Share by Type (2027-2032)
Table 21. Significant Companies of Lymphoma
Table 22. Significant Companies of Multiple Myeloma
Table 23. Global CAR T-Cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 24. Global CAR T-Cell Therapy Sales Value by Application (2021-2026) & (US$ Million)
Table 25. Global CAR T-Cell Therapy Sales Value by Application (2027-2032) & (US$ Million)
Table 26. Global CAR T-Cell Therapy Sales Value Share by Application (2021-2026)
Table 27. Global CAR T-Cell Therapy Sales Value Share by Application (2027-2032)
Table 28. Global CAR T-Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 29. Global CAR T-Cell Therapy Sales Value by Region (2021-2026) & (US$ Million)
Table 30. Global CAR T-Cell Therapy Sales Value Share by Region (2021-2026)
Table 31. Global CAR T-Cell Therapy Sales Value by Region (2027-2032) & (US$ Million)
Table 32. Global CAR T-Cell Therapy Sales Value Share by Region (2027-2032)
Table 33. Global CAR T-Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Global CAR T-Cell Therapy Sales Value by Country (2021-2026) & (US$ Million)
Table 35. Global CAR T-Cell Therapy Sales Value Market Share by Country (2021-2026)
Table 36. Global CAR T-Cell Therapy Sales Value by Country (2027-2032) & (US$ Million)
Table 37. Global CAR T-Cell Therapy Sales Value Market Share by Country (2027-2032)
Table 38. J & J Company Information
Table 39. J & J Business Overview
Table 40. J & J CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 41. J & J CAR T-Cell Therapy Product Portfolio
Table 42. J & J Recent Development
Table 43. Novartis Company Information
Table 44. Novartis Business Overview
Table 45. Novartis CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 46. Novartis CAR T-Cell Therapy Product Portfolio
Table 47. Novartis Recent Development
Table 48. Sorrento Therapeutics(Pipeline) Company Information
Table 49. Sorrento Therapeutics(Pipeline) Business Overview
Table 50. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 51. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
Table 52. Sorrento Therapeutics(Pipeline) Recent Development
Table 53. Mustang Bio(Pipeline) Company Information
Table 54. Mustang Bio(Pipeline) Business Overview
Table 55. Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 56. Mustang Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
Table 57. Mustang Bio(Pipeline) Recent Development
Table 58. JW Therapeutics Company Information
Table 59. JW Therapeutics Business Overview
Table 60. JW Therapeutics CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 61. JW Therapeutics CAR T-Cell Therapy Product Portfolio
Table 62. JW Therapeutics Recent Development
Table 63. Gilead Sciences Company Information
Table 64. Gilead Sciences Business Overview
Table 65. Gilead Sciences CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 66. Gilead Sciences CAR T-Cell Therapy Product Portfolio
Table 67. Gilead Sciences Recent Development
Table 68. FOSUNKite Company Information
Table 69. FOSUNKite Business Overview
Table 70. FOSUNKite CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. FOSUNKite CAR T-Cell Therapy Product Portfolio
Table 72. FOSUNKite Recent Development
Table 73. Celyad(Pipeline) Company Information
Table 74. Celyad(Pipeline) Business Overview
Table 75. Celyad(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 76. Celyad(Pipeline) CAR T-Cell Therapy Product Portfolio
Table 77. Celyad(Pipeline) Recent Development
Table 78. Cellectis(Pipeline) Company Information
Table 79. Cellectis(Pipeline) Business Overview
Table 80. Cellectis(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 81. Cellectis(Pipeline) CAR T-Cell Therapy Product Portfolio
Table 82. Cellectis(Pipeline) Recent Development
Table 83. CARsgen Therapeutics (Pipeline) Company Information
Table 84. CARsgen Therapeutics (Pipeline) Business Overview
Table 85. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 86. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product Portfolio
Table 87. CARsgen Therapeutics (Pipeline) Recent Development
Table 88. Bristol-Myers Squibb Company Information
Table 89. Bristol-Myers Squibb Business Overview
Table 90. Bristol-Myers Squibb CAR T-Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Bristol-Myers Squibb CAR T-Cell Therapy Product Portfolio
Table 92. Bristol-Myers Squibb Recent Development
Table 93. Bluebird Bio(Pipeline) Company Information
Table 94. Bluebird Bio(Pipeline) Business Overview
Table 95. Bluebird Bio(Pipeline) CAR T-Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Bluebird Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
Table 97. Bluebird Bio(Pipeline) Recent Development
Table 98. Autolus Therapeutics(Pipeline) Company Information
Table 99. Autolus Therapeutics(Pipeline) Business Overview
Table 100. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
Table 102. Autolus Therapeutics(Pipeline) Recent Development
Table 103. Allogene Therapeutics(Pipeline) Company Information
Table 104. Allogene Therapeutics(Pipeline) Business Overview
Table 105. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
Table 107. Allogene Therapeutics(Pipeline) Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Authors List of This Report
Table 110. Secondary Sources
Table 111. Primary Sources
List of Figures
Figure 1. CAR T-Cell Therapy Product Image
Figure 2. Global CAR T-Cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global CAR T-Cell Therapy Market Size (2021-2032) & (US$ Million)
Figure 4. Global CAR T-Cell Therapy Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. CD19 - Targeted Image
Figure 8. BCMA - Targeted Image
Figure 9. Global CAR T-Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global CAR T-Cell Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 11. Global CAR T-Cell Therapy Sales Value Share by Type (2021-2032)
Figure 12. Lymphoma Image
Figure 13. Multiple Myeloma Image
Figure 14. Global CAR T-Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 15. Global CAR T-Cell Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 16. Global CAR T-Cell Therapy Sales Value Share by Application (2021-2032)
Figure 17. Global CAR T-Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 18. Global CAR T-Cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 19. North America CAR T-Cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 20. North America CAR T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 21. Europe CAR T-Cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 22. Europe CAR T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 23. Asia-Pacific CAR T-Cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 24. Asia-Pacific CAR T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 25. South America CAR T-Cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 26. South America CAR T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 27. Middle East & Africa CAR T-Cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 28. Middle East & Africa CAR T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 29. USA CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 30. USA CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 31. USA CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 32. Canada CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 33. Canada CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 34. Canada CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 35. Mexico CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 36. Mexico CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 37. Mexico CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 38. Germany CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 39. Germany CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 40. Germany CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 41. France CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 42. France CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 43. France CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 44. U.K. CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. U.K. CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. U.K. CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. Italy CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. Italy CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. Italy CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Spain CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Spain CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Spain CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. Russia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. Russia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. Russia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. Netherlands CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. Netherlands CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. Netherlands CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. Nordic Countries CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. Nordic Countries CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. Nordic Countries CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. China CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. China CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. China CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. Japan CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. Japan CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. Japan CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. South Korea CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. South Korea CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. South Korea CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. India CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. India CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. India CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. Australia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. Australia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. Australia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. Southeast Asia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. Southeast Asia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. Southeast Asia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. Brazil CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. Brazil CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. Brazil CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. Argentina CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. Argentina CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. Argentina CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. Chile CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. Chile CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. Chile CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Colombia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Colombia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Colombia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Peru CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Peru CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Peru CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Saudi Arabia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Saudi Arabia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Saudi Arabia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Israel CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Israel CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Israel CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. UAE CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. UAE CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. UAE CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. Turkey CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. Turkey CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. Turkey CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Iran CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Iran CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Iran CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Egypt CAR T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Egypt CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Egypt CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. Years Considered
Figure 114. Research Process
Figure 115. Key Executives Interviewed
Scope & coverage.
Types
- CD19 - Targeted
- BCMA - Targeted
Applications
- Lymphoma
- Multiple Myeloma
Companies covered
- J & J
- Novartis
- Sorrento Therapeutics(Pipeline)
- Mustang Bio(Pipeline)
- JW Therapeutics
- Gilead Sciences
- FOSUNKite
- Celyad(Pipeline)
- Cellectis(Pipeline)
- CARsgen Therapeutics (Pipeline)
- Bristol-Myers Squibb
- Bluebird Bio(Pipeline)
- Autolus Therapeutics(Pipeline)
- Allogene Therapeutics(Pipeline)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global CAR T-Cell Therapy Market Size, 2021 VS 2025 VS 2032
- 1.3 Global CAR T-Cell Therapy Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 CAR T-Cell Therapy Market Dynamics
- 2.1 CAR T-Cell Therapy Industry Trends
- 2.2 CAR T-Cell Therapy Industry Drivers
- 2.3 CAR T-Cell Therapy Industry Opportunities and Challenges
- 2.4 CAR T-Cell Therapy Industry Restraints
3 CAR T-Cell Therapy Market by Company
- 3.1 Global CAR T-Cell Therapy Company Revenue Ranking in 2025
- 3.2 Global CAR T-Cell Therapy Revenue by Company (2021-2026)
- 3.3 Global CAR T-Cell Therapy Company Ranking (2024-2026)
- 3.4 Global CAR T-Cell Therapy Company Manufacturing Base and Headquarters
- 3.5 Global CAR T-Cell Therapy Company Product Type and Application
- 3.6 Global CAR T-Cell Therapy Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 CAR T-Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 CAR T-Cell Therapy Market by Type
- 4.1 CAR T-Cell Therapy Type Introduction
- 4.1.1 CD19 - Targeted
- 4.1.2 BCMA - Targeted
- 4.2 Global CAR T-Cell Therapy Sales Value by Type
- 4.2.1 Global CAR T-Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global CAR T-Cell Therapy Sales Value by Type (2021-2032)
- 4.2.3 Global CAR T-Cell Therapy Sales Value Share by Type (2021-2032)
5 CAR T-Cell Therapy Market by Application
- 5.1 CAR T-Cell Therapy Application Introduction
- 5.1.1 Lymphoma
- 5.1.2 Multiple Myeloma
- 5.2 Global CAR T-Cell Therapy Sales Value by Application
- 5.2.1 Global CAR T-Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global CAR T-Cell Therapy Sales Value by Application (2021-2032)
- 5.2.3 Global CAR T-Cell Therapy Sales Value Share by Application (2021-2032)
6 CAR T-Cell Therapy Regional Value Analysis
- 6.1 Global CAR T-Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global CAR T-Cell Therapy Sales Value by Region (2021-2032)
- 6.2.1 Global CAR T-Cell Therapy Sales Value by Region: 2021-2026
- 6.2.2 Global CAR T-Cell Therapy Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America CAR T-Cell Therapy Sales Value (2021-2032)
- 6.3.2 North America CAR T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe CAR T-Cell Therapy Sales Value (2021-2032)
- 6.4.2 Europe CAR T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific CAR T-Cell Therapy Sales Value (2021-2032)
- 6.5.2 Asia-Pacific CAR T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America CAR T-Cell Therapy Sales Value (2021-2032)
- 6.6.2 South America CAR T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa CAR T-Cell Therapy Sales Value (2021-2032)
- 6.7.2 Middle East & Africa CAR T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 CAR T-Cell Therapy Country-level Value Analysis
- 7.1 Global CAR T-Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global CAR T-Cell Therapy Sales Value by Country (2021-2032)
- 7.2.1 Global CAR T-Cell Therapy Sales Value by Country (2021-2026)
- 7.2.2 Global CAR T-Cell Therapy Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.3.2 USA CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.7.2 France CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.14.2 China CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.17.2 India CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt CAR T-Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt CAR T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt CAR T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 J & J
- 8.1.1 J & J Company Information
- 8.1.2 J & J Business Overview
- 8.1.3 J & J CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.1.4 J & J CAR T-Cell Therapy Product Portfolio
- 8.1.5 J & J Recent Developments
- 8.2 Novartis
- 8.2.1 Novartis Company Information
- 8.2.2 Novartis Business Overview
- 8.2.3 Novartis CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.2.4 Novartis CAR T-Cell Therapy Product Portfolio
- 8.2.5 Novartis Recent Developments
- 8.3 Sorrento Therapeutics(Pipeline)
- 8.3.1 Sorrento Therapeutics(Pipeline) Company Information
- 8.3.2 Sorrento Therapeutics(Pipeline) Business Overview
- 8.3.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.3.4 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
- 8.3.5 Sorrento Therapeutics(Pipeline) Recent Developments
- 8.4 Mustang Bio(Pipeline)
- 8.4.1 Mustang Bio(Pipeline) Company Information
- 8.4.2 Mustang Bio(Pipeline) Business Overview
- 8.4.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.4.4 Mustang Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
- 8.4.5 Mustang Bio(Pipeline) Recent Developments
- 8.5 JW Therapeutics
- 8.5.1 JW Therapeutics Company Information
- 8.5.2 JW Therapeutics Business Overview
- 8.5.3 JW Therapeutics CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.5.4 JW Therapeutics CAR T-Cell Therapy Product Portfolio
- 8.5.5 JW Therapeutics Recent Developments
- 8.6 Gilead Sciences
- 8.6.1 Gilead Sciences Company Information
- 8.6.2 Gilead Sciences Business Overview
- 8.6.3 Gilead Sciences CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.6.4 Gilead Sciences CAR T-Cell Therapy Product Portfolio
- 8.6.5 Gilead Sciences Recent Developments
- 8.7 FOSUNKite
- 8.7.1 FOSUNKite Company Information
- 8.7.2 FOSUNKite Business Overview
- 8.7.3 FOSUNKite CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.7.4 FOSUNKite CAR T-Cell Therapy Product Portfolio
- 8.7.5 FOSUNKite Recent Developments
- 8.8 Celyad(Pipeline)
- 8.8.1 Celyad(Pipeline) Company Information
- 8.8.2 Celyad(Pipeline) Business Overview
- 8.8.3 Celyad(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.8.4 Celyad(Pipeline) CAR T-Cell Therapy Product Portfolio
- 8.8.5 Celyad(Pipeline) Recent Developments
- 8.9 Cellectis(Pipeline)
- 8.9.1 Cellectis(Pipeline) Company Information
- 8.9.2 Cellectis(Pipeline) Business Overview
- 8.9.3 Cellectis(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.9.4 Cellectis(Pipeline) CAR T-Cell Therapy Product Portfolio
- 8.9.5 Cellectis(Pipeline) Recent Developments
- 8.10 CARsgen Therapeutics (Pipeline)
- 8.10.1 CARsgen Therapeutics (Pipeline) Company Information
- 8.10.2 CARsgen Therapeutics (Pipeline) Business Overview
- 8.10.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.10.4 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product Portfolio
- 8.10.5 CARsgen Therapeutics (Pipeline) Recent Developments
- 8.11 Bristol-Myers Squibb
- 8.11.1 Bristol-Myers Squibb Company Information
- 8.11.2 Bristol-Myers Squibb Business Overview
- 8.11.3 Bristol-Myers Squibb CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.11.4 Bristol-Myers Squibb CAR T-Cell Therapy Product Portfolio
- 8.11.5 Bristol-Myers Squibb Recent Developments
- 8.12 Bluebird Bio(Pipeline)
- 8.12.1 Bluebird Bio(Pipeline) Company Information
- 8.12.2 Bluebird Bio(Pipeline) Business Overview
- 8.12.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.12.4 Bluebird Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
- 8.12.5 Bluebird Bio(Pipeline) Recent Developments
- 8.13 Autolus Therapeutics(Pipeline)
- 8.13.1 Autolus Therapeutics(Pipeline) Company Information
- 8.13.2 Autolus Therapeutics(Pipeline) Business Overview
- 8.13.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.13.4 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
- 8.13.5 Autolus Therapeutics(Pipeline) Recent Developments
- 8.14 Allogene Therapeutics(Pipeline)
- 8.14.1 Allogene Therapeutics(Pipeline) Company Information
- 8.14.2 Allogene Therapeutics(Pipeline) Business Overview
- 8.14.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.14.4 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
- 8.14.5 Allogene Therapeutics(Pipeline) Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst